Related Experiment Videos

Class effects of statins in elderly patients with congestive heart failure: a population-based analysis

Stéphane Rinfret1, Hassan Behlouli, Mark J Eisenberg

  • 1Division of Cardiology, Department of Medicine, Centre Hospitalier de l'Université de Montréal, University of Montreal, Montreal, Quebec, Canada.

American Heart Journal
|January 25, 2008
PubMed

Insights

Statins show a class effect in reducing mortality for patients with congestive heart failure (CHF). This benefit is observed even at low doses, suggesting a consistent protective impact across different statin medications.

Area of Science:

  • Cardiology
  • Pharmacology
  • Public Health

Background:

  • Long-term statin use is known to decrease mortality in patients with congestive heart failure (CHF).
  • The question of whether statins exhibit a class effect in this patient population remains unanswered.

Purpose of the Study:

  • To investigate if statins demonstrate a class effect in reducing long-term mortality among elderly Canadian patients diagnosed with CHF.
  • To compare the effectiveness of atorvastatin, simvastatin, pravastatin, and lovastatin in this context.

Main Methods:

  • Analysis of long-term mortality data for Canadian patients (≥65 years) hospitalized with CHF between 1998 and 2002.
  • Utilized merged administrative data from Quebec, Ontario, and British Columbia.
  • Compared mortality rates among patients prescribed different statin medications, controlling for various clinical factors and time-dependent covariates.

Main Results:

  • The study included 15,368 patients; atorvastatin was prescribed to 43.4%, simvastatin to 27.7%, pravastatin to 20.9%, and lovastatin to 8.0%.
  • Pravastatin, lovastatin, and simvastatin showed similar mortality-preventing effectiveness compared to atorvastatin (adjusted HRs ranging from 0.92 to 1.02).
  • Time-dependent exposure to statins was significantly protective against mortality, with most patients receiving low dosages (< or = 20 mg).

Conclusions:

  • Statins appear to exert a class effect in patients with congestive heart failure, indicating similar efficacy across different agents.
  • The observed benefits of statins in reducing mortality in CHF patients are largely independent of the specific drug dosage used.
  • Low-dose statin therapy demonstrates significant protective effects against mortality in this population.
Abstract

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Heart Failure Drugs: &#946;-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...